Guus_Geluk schreef op 4 juni 2014 08:28:
[...]
Roth heeft ook nog een koersdoel van 3 dollar (ruim 2 euro) voor Pharming staan.
PHARM: Management Meeting and Approval
in Israel; Target Upped to $3A discussion with management indicated a flurry of background activities
ahead of the April PDUFA for Ruconest. Additionally, Pharming announced
that partner MegaPharm received marketing authorization and reimbursement
approval for Ruconest in Israel. All eyes remain on the April 2014 PDUFA date
for Ruconest in the U.S.
Reiterate Buy and raising price target to $3 from $2.roth2.bluematrix.com/sellside/EmailDo...